HIV-1 neutralizing antibodies and uses thereof
The invention is directed to HIV-1 neutralizing antibodies and methods for their uses.
1. A recombinant antibody or fragment thereof comprising:
a heavy chain variable region comprising a heavy chain complementarity determining region (HCDR)1, a HCDR2, and a HCDR3 comprising amino acids at positions 26-33, 51-60 and 99-121 of SEQ ID NO: 230, SEQ ID NO: 240 or SEQ ID NO: 241, respectively; and
a light chain variable region comprising a light chain complementarity determining region (LCDR)1, a LCDR2, and a LCDR3, comprising amino acids at positions 27-32, 50-52 and 89-99 of SEQ ID NO: 253, SEQ ID NO: 255 or SEQ ID NO: 261 respectively, wherein the antibody or fragment thereof binds gp41 MPER of HIV-1 envelope.
2. A recombinant antibody or fragment thereof comprising:
a heavy chain variable region comprising heavy chain complementarity determining regions (HCDRs) that have an overall HCDR sequence identity of at least 90% to HCDR amino acids at positions 26-33, 51-60 and 99-121 of SEQ ID NO: 230, SEQ ID NO:240, or SEQ ID NO:241; and
a light chain variable region comprising light chain complementarity determining regions (LCDRs) that have an overall LCDR sequence identity of at least 90% to LCDR amino acids at positions 27-32, 50-52 and 89-99 of SEQ ID NO: 253, SEQ ID NO: 255 or SEQ ID NO: 261;
wherein the antibody or fragment thereof binds gp41 MPER of HIV-1 envelope.
3. The recombinant antibody or fragment thereof of claim 1 , comprising:
a heavy chain variable region comprising a HCDR1, a HCDR2, and a HCDR3 comprising amino acids at positions 26-33, 51-60 and 99-121 of SEQ ID NO: 230 and
a LCDR1, a LCDR2, and a LCDR3, comprising amino acids at positions 27-32, 50-52 and 89-99 of SEQ ID NO: 253.
4. The recombinant antibody or fragment thereof of claim 1 , comprising:
a heavy chain variable region comprising a HCDR1, a HCDR2, and a HCDR3 comprising amino acids at positions 26-33, 51-60 and 99-121 of SEQ ID NO: 230 and
a LCDR1, a LCDR2, and a LCDR3, comprising amino acids at positions 27-32, 50-52 and 89-99 of SEQ ID NO: 255.
5. The recombinant antibody or fragment thereof of claim 1 comprising:
a heavy chain variable region comprising a HCDR1, a HCDR2, and a HCDR3 comprising amino acids at positions 26-33, 51-60 and 99-121 of SEQ ID NO: 240 and
a LCDR1, a LCDR2, and a LCDR3, comprising amino acids at positions 27-32, 50-52 and 89-99 of SEQ ID NO: 261.
6. The recombinant antibody or fragment thereof of claim 1 comprising:
a heavy chain variable region comprising a HCDR1, a HCDR2, and a HCDR3 comprising amino acids at positions 26-33, 51-60 and 99-121 of SEQ ID NO: 241 and
a LCDR1, a LCDR2, and a LCDR3, comprising amino acids at positions 27-32, 50-52 and 89-99 of SEQ ID NO: 261.
7. The recombinant antibody or fragment thereof of claim 2 comprising:
a heavy chain variable region comprising heavy chain complementarity determining regions (HCDRs) that have an overall HCDR sequence identity of at least 90% to HCDR amino acids at positions 26-33, 51-60 and 99-121 of SEQ ID NO: 230; and
a light chain variable region comprising light chain complementarity determining regions (LCDRs) that have an overall LCDR sequence identity of at least 90% to LCDR amino acids at positions 27-32, 50-52 and 89-99 of SEQ ID NO: 253.
8. The recombinant antibody or fragment thereof of claim 2 comprising:
a heavy chain variable region comprising heavy chain complementarity determining regions (HCDRs) that have an overall HCDR sequence identity of at least 90% to HCDR amino acids at positions 26-33, 51-60 and 99-121 of SEQ ID NO: 230; and
a light chain variable region comprising light chain complementarity determining regions (LCDRs) that have an overall LCDR sequence identity of at least 90% to LCDR amino acids at positions 27-32, 50-52 and 89-99 of SEQ ID NO: 255.
9. The recombinant antibody or fragment thereof of claim 2 comprising:
a heavy chain variable region comprising heavy chain complementarity determining regions (HCDRs) that have an overall HCDR sequence identity of at least 90% to HCDR amino acids at positions 26-33, 51-60 and 99-121 of SEQ ID NO: 240; and
a light chain variable region comprising light chain complementarity determining regions (LCDRs) that have an overall LCDR sequence identity of at least 90% to LCDR amino acids at positions 27-32, 50-52 and 89-99 of SEQ ID NO: 261.
10. The recombinant antibody or fragment thereof of claim 2 comprising:
a heavy chain variable region comprising heavy chain complementarity determining regions (HCDRs) that have an overall HCDR sequence identity of at least 90% to HCDR amino acids at positions 26-33, 51-60 and 99-121 of SEQ ID NO: 241; and
a light chain variable region comprising light chain complementarity determining regions (LCDRs) that have an overall LCDR sequence identity of at least 90% to LCDR amino acids at positions 27-32, 50-52 and 89-99 of SEQ ID NO: 261.
11. The recombinant antibody or fragment thereof of claim 1 or 2 wherein the antibody or fragment thereof comprises the VH chain of SEQ ID NO: 230 and the VL chain of SEQ ID NO: 253.
12. The recombinant antibody or fragment thereof of claim 1 or 2 wherein the antibody or fragment thereof comprises the VH chain of SEQ ID NO: 230 and the VL chain of SEQ ID NO: 255.
13. The antibody or fragment thereof of claim 1 or 2 wherein the antibody or fragment thereof comprises the VH chain of SEQ ID NO: 240 and the VL chain of SEQ ID NO: 261.
14. The recombinant antibody or fragment thereof of claim 1 or 2 wherein the antibody or fragment thereof comprises the VH chain of SEQ ID NO: 241 and the VL chain of SEQ ID NO: 261.
15. The recombinant antibody of claim 2 , wherein the VH chain comprises one or more of a tryptophan amino acid residue at position 26, a tryptophan amino acid residue at position 28, a tryptophan amino acid residue at position 31, a tryptophan amino acid residue at position 52, a tryptophan amino acid residue at position 52b, a tryptophan amino acid residue at position 52c, a tryptophan amino acid residue at position 53, a tryptophan amino acid residue at position 73, a tryptophan amino acid residue at position 74, a tryptophan amino acid residue at position 75, a tryptophan amino acid residue at position 96, a tryptophan amino acid residue at position 97, a phenylalanine amino acid residue at position 97, a tryptophan amino acid residue at position 98, a tryptophan amino acid residue at position 99, a phenylalanine amino acid residue at position 100, an isoleucine amino acid residue at position 100, a leucine amino acid residue at position 100, a tryptophan amino acid residue at position 100a, a tryptophan amino acid residue at position 100b, a tryptophan amino acid residue at position 100c, a tryptophan amino acid residue at position 100d, a phenylalanine amino acid residue at position 100d, a tryptophan amino acid residue at position 100e, a tryptophan amino acid residue at position 100f, a tryptophan amino acid residue at position 100g, a tryptophan amino acid residue at position 100h, a tryptophan amino acid residue at position 100i, a tryptophan amino acid residue at position 100j, and a tryptophan amino acid residue at position 100k, wherein the recited positions are identified by Kabat numbering, and wherein the VL chain has an amino acid sequence of SEQ ID NO: 253 or SEQ ID NO: 255.
16. The recombinant antibody of claim 15 , wherein the VH chain comprises a tryptophan amino acid residue at position 100d, a phenylalanine amino acid residue at position 100d, a tryptophan amino acid residue at position 100a, or a combination thereof, wherein the recited positions are identified by Kabat numbering, and wherein the VL chain has an amino acid sequence of SEQ ID NO: 253 or SEQ ID NO: 255.
17. A bispecific antibody comprising the recombinant antibody or fragment thereof of any one of claim 1 or 2 .
18. The recombinant antibody or fragment thereof of claim 1 or 2 wherein the antibody or fragment thereof comprises an Fc portion that is modified compared to a naturally occurring Fc domain.
19. A pharmaceutical composition comprising any one of the antibodies or fragments thereof of any one of claim 1 or 2 , or any combination thereof.
20. The pharmaceutical composition of claim 19 , further comprising another HIV 1 neutralizing antibody.
21. A pharmaceutical composition comprising a vector, the vector comprising a nucleic acid encoding an antibody or fragment thereof comprising
a heavy chain variable region comprising heavy chain complementarity determining regions (HCDRs) that have an overall HCDR sequence identity of at least 90% to HCDR amino acids at positions 26-33, 51-60 and 99-121 of SEQ ID NO: 230, SEQ ID NO: 240, or SEQ ID NO: 241; and
a light chain variable region comprising light chain complementarity determining regions (LCDRs) that have an overall LCDR sequence identity of at least 90% to LCDR amino acids at positions 27-32, 50-52 and 89-99 of SEQ ID NO: 253, SEQ ID NO: 255, or SEQ ID NO: 261;
wherein the antibody or fragment thereof binds gp41 MPER of HIV-1 envelope.
22. A pharmaceutical composition comprising a vector, the vector comprising a nucleic acid encoding an antibody or fragment thereof comprising
a heavy chain variable region comprising heavy chain complementarity determining regions (HCDRs) that have an overall HCDR sequence identity of at least 90% to HCDR amino acids at positions 26-33, 51-60 and 99-121 of SEQ ID NO: 230, SEQ ID NO: 240, or SEQ ID NO: 241; and
a light chain variable region comprising light chain complementarity determining regions (LCDRs) that have an overall LCDR sequence identity of at least 90% to LCDR amino acids at positions 27-32, 50-52 and 89-99 of SEQ ID NO: 253, SEQ ID NO: 255, or SEQ ID NO: 261;
wherein the antibody or fragment thereof binds gp41 MPER of HIV-1 envelope.
23. The pharmaceutical composition of claim 21 or 22 , wherein the vector is suitable for gene delivery and expression.
24. A method to inhibit HIV-1 infection in a subject comprising administering to the subject the pharmaceutical composition of claim 19 in an effective amount.
25. The method of claim 24 wherein the pharmaceutical composition is administered in an effective regimen.
26. The method of claim 24 further comprising administering an additional HIV 1 neutralizing antibody.